Skip to main content
EnglishEN
European Commission logo print header

Corona Accelerated R&D in Europe

Project description

DEENESFRITPL

European consortium for coronavirus prevention, immunotherapy and drug discovery

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is the most serious health threat of this century. The EU-funded CARE project is a coalition of 37 academic institutions, pharmaceutical companies and non-profit research organisations. The main consortium objectives are to develop therapeutics for the emergency response to the current SARS-CoV-2 pandemic by drug repositioning and to address future outbreaks through drug and virus-neutralising antibody discovery. The potency and safety of the therapeutic drug candidates will be assessed in vitro and in animal models. Moreover, virus-neutralising monoclonal antibodies will be generated and immune markers will be identified. The final lead candidates will be advanced into Phase 1 and Phase 2 clinical trials in humans.

Objective

The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) pandemic has emerged as the largest global health threat to humanity in this century. According to the World Health Organisation Situation Report of March 28th 2020, 571,659 patients were diagnosed with Coronavirus Disease 2019 (COVID-19) and 26,493 deaths were reported globally. The wide spectrum of clinical symptoms, disease severity in high risk individuals, transmission efficiency and high mortality, raises an immediate need for vaccines or therapeutics. Given that the viral variant is new in the human population and emerged less than 4 months ago, there is no vaccine or approved therapies. The Corona Accelerated R&D in Europe (CARE) consortium is a coalition of 37 globally renowned academic institutions, pharmaceutical companies and non-profit research organizations who have committed to rapidly and efficiently address this emergent health threat, and the main objectives are: the development of therapeutics (i) to provide an emergency response towards the current COVID-19 pandemic by drug repositioning and (ii) to address the current and/or future coronavirus outbreaks by broad-spectrum small-molecule drug discovery and/or virus-neutralizing antibody discovery. To achieve this, a collection of repurposed drugs, focused libraries and small molecule libraries will be screened against SARS-CoV-2, other emerging SARS-CoV-2 clades and related coronavirus genera in phenotypic or target-based assays. A focused medicinal chemistry campaign will identify small-molecule hits, and Absorption, Distribution, Metabolism and Excretion (ADME), pharmacokinetic/pharmacodynamic (PK/PD), potency and safety of these therapeutic candidates will be assessed in vitro and in animal models. Virus-neutralizing monoclonal antibodies will be generated and further characterized. Immune markers will be identified contributing to the host immune responses to SARS-CoV-2 infections, and the correlation with clinical and virological outcomes will be determined. Finally, lead candidates will be advanced into Phase1 and Phase 2 clinical trials in humans. With this reactive response, the CARE consortium is dedicated to win the fight against coronavirus.

Fields of science

Keywords

Programme(s)

Topic(s)

Call for proposal

H2020-JTI-IMI2-2020-21-single-stage

See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution
€ 6 630 753,05
Address
Rue de tolbiac 101
75654 Paris
France

See on map
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Other funding
€ 570 962,00

Participants (42)

Share this page

Download

EC signature date 7 August 2020
Last update: 9 July 2023

My Booklet

Permalink: https://cordis.europa.eu/project/id/101005077

European Union, 2023